Ftse Mib
34.632,99
-0,55%
DAX
18.741,09
-0,14%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
70.941,12
-0,71%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ocuphire Pharma Inc (OCUP) Ocuphire Pharma Inc (OCUP) Notizie

OCUP

Ocuphire Pharma (OCUP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OCUP
DataOraFonteTitoloSimboloCompagnia
10/05/202422:35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCUPOcuphire Pharma Inc
10/05/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCUPOcuphire Pharma Inc
08/03/202423:20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OCUPOcuphire Pharma Inc
16/02/202422:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OCUPOcuphire Pharma Inc
15/02/202400:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCUPOcuphire Pharma Inc
15/02/202400:32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OCUPOcuphire Pharma Inc
24/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OCUPOcuphire Pharma Inc
11/01/202422:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OCUPOcuphire Pharma Inc
10/01/202423:00Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OCUPOcuphire Pharma Inc
27/09/202314:00PR Newswire (US)Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., TrNASDAQ:OCUPOcuphire Pharma Inc
14/08/202314:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OCUPOcuphire Pharma Inc
14/06/202322:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OCUPOcuphire Pharma Inc
09/06/202300:49Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OCUPOcuphire Pharma Inc
15/05/202314:23Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:OCUPOcuphire Pharma Inc
01/05/202322:16Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:OCUPOcuphire Pharma Inc
01/05/202322:13Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:OCUPOcuphire Pharma Inc
05/04/202323:05Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:OCUPOcuphire Pharma Inc
30/03/202323:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:OCUPOcuphire Pharma Inc
14/02/202320:04Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:OCUPOcuphire Pharma Inc
06/12/202222:50TipRanksAnalysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP) and Irhythm Technologies (IRTC)NASDAQ:OCUPOcuphire Pharma Inc
23/11/202222:15TipRanksJonesTrading Remains a Buy on Ocuphire Pharma (OCUP)NASDAQ:OCUPOcuphire Pharma Inc
07/11/202212:15TipRanksH.C. Wainwright Keeps Their Buy Rating on Ocuphire Pharma (OCUP)NASDAQ:OCUPOcuphire Pharma Inc
17/10/202212:25TipRanksOcuphire Pharma (OCUP) Receives a Buy from H.C. WainwrightNASDAQ:OCUPOcuphire Pharma Inc
15/08/202212:20TipRanksWall Street Analysts Are Bullish on Top Healthcare PicksNASDAQ:OCUPOcuphire Pharma Inc
10/06/202222:17Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:OCUPOcuphire Pharma Inc
22/05/202210:30TipRanksH.C. Wainwright Thinks Ocuphire Pharma’s Stock is Going to RecoverNASDAQ:OCUPOcuphire Pharma Inc
17/05/202222:38Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:OCUPOcuphire Pharma Inc
25/03/202211:16TipRanksOcuphire Pharma (OCUP) Gets a Buy Rating from H.C. WainwrightNASDAQ:OCUPOcuphire Pharma Inc
14/02/202222:20Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:OCUPOcuphire Pharma Inc
19/01/202220:45TipRanksOcuphire Pharma: A High-Risk, High-Reward StockNASDAQ:OCUPOcuphire Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OCUP

La tua Cronologia

BIT
UC3F8S
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network